GSK

eczema skin condition
Biotech

GSK posts phase 3 itch data as it closes in on FDA approval

GSK said patients on linerixibat reported reductions in itching that began after two weeks and persisted through the 24-week primary endpoint.
Nick Paul Taylor May 8, 2025 8:50am
colorful brain art model

GSK pens $2.5B pact for ABL's blood-brain barrier-bypassing tech

Apr 7, 2025 7:00am
layoffs

LifeMine lays off staff to focus on lead immunology asset

Mar 31, 2025 5:26pm
Board room C-suite meeting contract

Sanofi snatches GSK R&D leader

Mar 31, 2025 1:26pm
brain

GSK seeks link between shingles vax and lower dementia risk

Mar 25, 2025 5:00am
shingles vaccine vaccination checklist

Curevo clinches $110M, nabs Moncef Slaoui to lead board

Mar 17, 2025 10:44am